Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, January – September 2021

Jostein Starrfelt, Eirik Alnes Buanes, Lene Kristine Juvet, Trude Marie Lyngstad, Gunnar Øyvind Isaksson Rø, Lamprini Veneti, Hinta Meijerink
doi: https://doi.org/10.1101/2021.11.12.21266222
Jostein Starrfelt
1Department of Infection Control and Preparedness, Norwegian Institute of Public Health, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jostein.starrfelt@fhi.no
Eirik Alnes Buanes
2Norwegian Intensive Care and Pandemic Registry (NIPaR), Helse Bergen Health Trust, Bergen, Norway
3Department of Anaesthesiology and Intensive Care Haukeland University Hospital, Bergen, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lene Kristine Juvet
4Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway
5Department of Development and Analytics, Norwegian Institute of Public Health, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trude Marie Lyngstad
1Department of Infection Control and Preparedness, Norwegian Institute of Public Health, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gunnar Øyvind Isaksson Rø
5Department of Development and Analytics, Norwegian Institute of Public Health, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lamprini Veneti
1Department of Infection Control and Preparedness, Norwegian Institute of Public Health, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hinta Meijerink
4Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background SARS-CoV-2 vaccines show high effectiveness against infection and (severe) disease. However, few studies estimate population level vaccine effectiveness against multiple COVID-19 outcomes, by age and including homologous and heterologous vaccine regimens.

Methods Using Cox proportional hazard models on data from 4 293 544 individuals (99% of Norwegian adults), we estimated overall, age-, and product-specific vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, ICU admission and death in Norway, using data from national registries. Vaccine status was included as time-dependent variable and we adjusted for sex, pre-existing medical conditions, country of birth, county of residence, and crowded living conditions.

Findings Adjusted vaccine effectiveness among fully vaccinated is 72·1% (71·2–73·0) against SARS-CoV-2 infection, 92·9% (91·2–94·2) against hospitalisation, 95·5% (92·6–97·2) against ICU admission, and 88·0% (82·5–91·8) against death. Among partially vaccinated, the effectiveness is 24·3% (22·3–26·2) against infection and 82·7% (77·7–86·6) against hospitalisation. Vaccine effectiveness against infection is 84·7% (83·1-86·1) for heterologous mRNA vaccine regimens, 78·3% (76·8-79·7) for Spikevax (Moderna; mRNA-1273), 69·7% (68·6-70·8) for Comirnaty (Pfizer/BioNTech; BNT162b2), and 60·7% (57·5-63·6) for Vaxzevria (AstraZeneca; ChAdOx nCoV-19; AZD1222) with a mRNA dose among fully vaccinated.

Interpretation We demonstrate good protection against SARS-CoV-2 infection and severe disease in fully vaccinated, including heterologous vaccine regimens, which could facilitate rapid immunization. Partially vaccinated were less likely to get severe disease than unvaccinated, though protection against infection was not as high, which could be essential in making vaccine prioritisation policies especially when availability is limited.

Funding Norwegian Institute of Public Health, Helse Bergen Health Trust

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was performed without external funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical approval was granted by Regional Committees for Medical and Health Research Ethics (REC) South East, Norway (reference number 122745).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Legal restrictions prevent sharing the dataset used in this study. However, researchers are able to request access to linked data from the same registries, as per normal procedure for conducting health research on registry data in Norway. Further information on the preparedness registry, including access to data from each data source, is available at https://www.fhi.no/en/id/infectiousdiseases/coronavirus/emergency-preparedness-register-for-covid-19/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted November 12, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, January – September 2021
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, January – September 2021
Jostein Starrfelt, Eirik Alnes Buanes, Lene Kristine Juvet, Trude Marie Lyngstad, Gunnar Øyvind Isaksson Rø, Lamprini Veneti, Hinta Meijerink
medRxiv 2021.11.12.21266222; doi: https://doi.org/10.1101/2021.11.12.21266222
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, January – September 2021
Jostein Starrfelt, Eirik Alnes Buanes, Lene Kristine Juvet, Trude Marie Lyngstad, Gunnar Øyvind Isaksson Rø, Lamprini Veneti, Hinta Meijerink
medRxiv 2021.11.12.21266222; doi: https://doi.org/10.1101/2021.11.12.21266222

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (160)
  • Allergy and Immunology (412)
  • Anesthesia (90)
  • Cardiovascular Medicine (855)
  • Dentistry and Oral Medicine (156)
  • Dermatology (97)
  • Emergency Medicine (247)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (392)
  • Epidemiology (8534)
  • Forensic Medicine (4)
  • Gastroenterology (381)
  • Genetic and Genomic Medicine (1739)
  • Geriatric Medicine (167)
  • Health Economics (370)
  • Health Informatics (1234)
  • Health Policy (618)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (369)
  • Infectious Diseases (except HIV/AIDS) (10271)
  • Intensive Care and Critical Care Medicine (552)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (210)
  • Neurology (1666)
  • Nursing (97)
  • Nutrition (247)
  • Obstetrics and Gynecology (325)
  • Occupational and Environmental Health (450)
  • Oncology (925)
  • Ophthalmology (262)
  • Orthopedics (100)
  • Otolaryngology (172)
  • Pain Medicine (110)
  • Palliative Medicine (40)
  • Pathology (249)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (246)
  • Primary Care Research (205)
  • Psychiatry and Clinical Psychology (1757)
  • Public and Global Health (3826)
  • Radiology and Imaging (622)
  • Rehabilitation Medicine and Physical Therapy (317)
  • Respiratory Medicine (518)
  • Rheumatology (207)
  • Sexual and Reproductive Health (164)
  • Sports Medicine (156)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (100)
  • Urology (74)